当前位置：
X-MOL 学术
›
Am. J. Hematol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial
American Journal of Hematology ( IF 12.8 ) Pub Date : 2024-04-05 , DOI: 10.1002/ajh.27304 Paula Cramer 1 , Julia von Tresckow 1, 2 , Anna‐Maria Fink 1 , Sandra Robrecht 1 , Adam Giza 1 , Eugen Tausch 3 , Lothar Müller 4 , Wolfgang Knauf 5 , Matthias Zingerle 6 , Othman Al‐Sawaf 1 , Petra Langerbeins 1 , Kirsten Fischer 1 , Karl‐Anton Kreuzer 1 , Michael Kneba 7 , Clemens‐Martin Wendtner 8 , Stephan Stilgenbauer 3 , Barbara Eichhorst 1 , Michael Hallek 1
American Journal of Hematology ( IF 12.8 ) Pub Date : 2024-04-05 , DOI: 10.1002/ajh.27304 Paula Cramer 1 , Julia von Tresckow 1, 2 , Anna‐Maria Fink 1 , Sandra Robrecht 1 , Adam Giza 1 , Eugen Tausch 3 , Lothar Müller 4 , Wolfgang Knauf 5 , Matthias Zingerle 6 , Othman Al‐Sawaf 1 , Petra Langerbeins 1 , Kirsten Fischer 1 , Karl‐Anton Kreuzer 1 , Michael Kneba 7 , Clemens‐Martin Wendtner 8 , Stephan Stilgenbauer 3 , Barbara Eichhorst 1 , Michael Hallek 1
Affiliation
|
Treatment regimen an iwCLL and MRD response.
中文翻译：
苯达莫司汀，其次是 obinutuzumab 和 idelalisib 治疗慢性淋巴细胞白血病 (CLL2-BCG)：多中心、开放标签 II 期试验的最终分析
治疗方案 iwCLL 和 MRD 反应。
更新日期：2024-04-05
中文翻译：
苯达莫司汀，其次是 obinutuzumab 和 idelalisib 治疗慢性淋巴细胞白血病 (CLL2-BCG)：多中心、开放标签 II 期试验的最终分析
治疗方案 iwCLL 和 MRD 反应。
京公网安备 11010802027423号